Table 2.

Nanosystems applied to systemic microbial infections treatment in different clinical stages.

Drug	Clinical Trial	Indication	Trial Phase	Intervention treatment
Amikacin	Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria	Mycobacterium Infections, Nontuberculous	Phase 2	Ciprofloxacin dispersion for inhalation (Liquid mixture of liposomally encapsulated and un encapsulated ciprofloxacin) Placebo: Liquid formulation of empty liposomes.
Amikacin	Study to Evaluate Ecacy of inhaled amikacin loaded-liposome combined with multi-drug regimen, Compared to Multi-drug Regimen Alone (CONVERT)	Mycobacterium Infections, Nontuberculous	Phase 3	Liposomal Amikacin for Inhalation, 590 m.g
Amphotericine B	Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients (AMBIDEX)	Candida	Phase 4	Amphotericine in liposome (Ambisome®); 2 IV infusions separated by one week 10 mg/kg per injection.
Micafungin And Amphotericin B	Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia	Candidiasis	Phase 3	Micafungin IV; Liposomal Amphotericin B IV.
Amphotericine B	CRITIC - Treatment of Candidemia and Invasive Candidiasis (CRITIC)	Candidemia Invasive Candidiasis	Phase 4	AmBisome® 2 mg/kg/day in a unique daily IV administration.
Voriconazole; Amphotericin B; Fluconazole	A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.	Candidiasis	Phase 3	VFEND® I.V., Oral; Conventional amphotericin B; Diflucan IV, oral.